Evidence map›Paper›PMID 24068937›Full record

ArticlePLoS pathogens2013

Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming.

Michael J McClellan, C David Wood, Opeoluwa Ojeniyi, Tim J Cooper, Aditi Kanhere, Aaron Arvey, Helen M Webb, Richard D Palermo, Marie L Harth-Hertle, Bettina Kempkes and 2 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 96 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Multiple sclerosis and infection: history, EBV, and the search for mechanism.Microbiology and molecular biology reviews : MMBR · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Michael J McClellanSchool of Life Sciences, John Maynard-Smith Building, University of Sussex, Falmer, Brighton, United Kingdom.
C David Wood
Opeoluwa Ojeniyi
Tim J Cooper
Aditi Kanhere
Aaron Arvey
Helen M Webb
Richard D Palermo
Marie L Harth-Hertle
Bettina Kempkes
Richard G Jenner
Michelle J West
University of Sussex · GBHelmholtz Zentrum München · DEMemorial Sloan Kettering Cancer Center · USMRC Laboratory for Molecular Cell Biology · GBUniversity College London · GB

Funding

Medical Research Council G0600081Wellcome Trust
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) epigenetically reprogrammes B-lymphocytes to drive immortalization and facilitate viral persistence. Host-cell transcription is perturbed principally through the actions of EBV EBNA 2, 3A, 3B and 3C, with cellular genes deregulated by specific combinations of these EBNAs through unknown mechanisms. Comparing human genome binding by these viral transcription factors, we discovered that 25% of binding sites were shared by EBNA 2 and the EBNA 3s and were located predominantly in enhancers. Moreover, 80% of potential EBNA 3A, 3B or 3C target genes were also targeted by EBNA 2, implicating extensive interplay between EBNA 2 and 3 proteins in cellular reprogramming. Investigating shared enhancer sites neighbouring two new targets (WEE1 and CTBP2) we discovered that EBNA 3 proteins repress transcription by modulating enhancer-promoter loop formation to establish repressive chromatin hubs or prevent assembly of active hubs. Re-ChIP analysis revealed that EBNA 2 and 3 proteins do not bind simultaneously at shared sites but compete for binding thereby modulating enhancer-promoter interactions. At an EBNA 3-only intergenic enhancer site between ADAM28 and ADAMDEC1 EBNA 3C was also able to independently direct epigenetic repression of both genes through enhancer-promoter looping. Significantly, studying shared or unique EBNA 3 binding sites at WEE1, CTBP2, ITGAL (LFA-1 alpha chain), BCL2L11 (Bim) and the ADAMs, we also discovered that different sets of EBNA 3 proteins bind regulatory elements in a gene and cell-type specific manner. Binding profiles correlated with the effects of individual EBNA 3 proteins on the expression of these genes, providing a molecular basis for the targeting of different sets of cellular genes by the EBNA 3s. Our results therefore highlight the influence of the genomic and cellular context in determining the specificity of gene deregulation by EBV and provide a paradigm for host-cell reprogramming through modulation of enhancer-promoter interactions by viral transcription factors.

Indexed as

Cellular ReprogrammingEnhancer Elements, GeneticGene TargetingModels, BiologicalAlcohol OxidoreductasesBinding, CompetitiveBinding SitesCell Cycle ProteinsCell LineCo-Repressor ProteinsEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensHerpesvirus 4, HumanHost-Pathogen InteractionsHumansNerve Tissue ProteinsAlcohol OxidoreductasesCell Cycle ProteinsCo-Repressor ProteinsCTBP2 protein, humanEBNA-2 protein, Human herpesvirus 4EBNA-3A antigenEBNA-3B antigenEBNA-3C, epstein-barr virusEpstein-Barr Virus Nuclear AntigensNerve Tissue ProteinsNuclear ProteinsProtein-Tyrosine KinasesRecombinant ProteinsRepressor ProteinsViral ProteinsWEE1 protein, human

Identifiers

PMID24068937
PMCPMC3771879
OpenAlexW2089219418

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.